Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Hyaluronate,Triamcinolone Hexacetonide
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Anika’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study
Details : Cingal (sodium hyaluronate) combination product of cross-linked hyaluronic acid (HA) proven to provide long lasting pain relief through 6 months plus TH steroid to provide fast, short-term pain relief.
Brand Name : Cingal
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 01, 2022
Lead Product(s) : Sodium Hyaluronate,Triamcinolone Hexacetonide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?